Hubertus von Baumbach, Boehringer Ingelheim's chairman of the board of managing directors, at its annual press conference on April 16, 2024 (Arne Dedert/picture-alliance/dpa/AP Images)
April 16, 2024 07:43 AM EDTUpdated April 30, 10:56 AM
Pharma

Cor­rec­tion: Boehringer In­gel­heim touts 10-year plan as it eyes over­tak­ing Bay­er as Ger­many’s largest phar­ma

Ayisha Sharma

News Reporter

Anna Brown

News Reporter

Boehringer In­gel­heim put the spot­light on a pipeline ripe with mile­stones over the next decade dur­ing its full-year 2023 call with the press.

Dri­ven in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times